Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

Innovations and highlights in the Pharma industry 

Dive deep into the world of Pharma with Zamann’s Expert Blog. Our industry-leading professionals share insights on global project management, quality consultancy, digitalization, and more. Stay updated with trends and innovations transforming the Pharma industry. 

News and more

FDA Speeds Up IND Reviews; Experts Say Protocol Design Still Drives Success

The U.S. Department of Health and Human Services (HHS) has introduced Operation Trialblazer, a multi-agency initiative designed to accelerate early-stage drug development and modernize clinical research across the United States. Working alongside the FDA and the National Institutes of Health
  • News
FDA Speeds Up IND Reviews; Experts Say Protocol Design Still Drives Success

Good Manufacturing Practices in Australia in 2026: TGA GMP Inspection Guide

Understand how TGA GMP inspections work in Australia, explore official GMP guidance PDFs, review common inspection findings, and use a practical GMP compliance checklist to strengthen pharmaceutical quality systems and improve inspection readiness before your next regulatory audit.
  • Blog, Quality Management System
Illustration of a pharmaceutical manufacturing facility showing TGA GMP inspection activities, pharmaceutical quality system controls, and GMP inspection readiness based on Australia GMP guidelines.

FDA Transparency Hits a Roadblock; Why Drug Rejection Letters Suddenly Stopped

The U.S. Food and Drug Administration (FDA) has temporarily paused the public release of Complete Response Letters (CRLs). The agency made the decision after an unnamed pharmaceutical company challenged the policy over confidentiality concerns. The move temporarily suspends one of
  • News
FDA Transparency Hits a Roadblock; Why Drug Rejection Letters Suddenly Stopped

China Drives Pharma Innovation; Regulatory Scrutiny Is Rising Alongside It

AstraZeneca and GSK have announced separate agreements with China's Sino Biopharm, reinforcing a growing trend of cross-border pharmaceutical partnerships. AstraZeneca licensed an investigational respiratory medicine, while GSK expanded its commercial collaboration in China. The announcements come as regulators increasingly examine
  • News
China Drives Pharma Innovation; Regulatory Scrutiny Is Rising Alongside It

Good Manufacturing Practices in Canada in 2026: Health Canada GMP Inspection Guide

Learn how Health Canada GMP inspections evaluate pharmaceutical manufacturers, explore official guidance documents, review common inspection findings, and use practical checklists to strengthen compliance and prepare for successful Drug Establishment Licence inspections.
  • Blog, Quality Management System
Pharmaceutical quality specialist reviewing manufacturing compliance during a Health Canada inspection, illustrating GMP in Canada, GUI 0001 requirements, and Drug Establishment Licence Canada readiness.

ConcertAI Expands CancerLinQ; Trust in Clinical AI Now Depends on Validation

ConcertAI has expanded its CancerLinQ platform beyond quality reporting into an AI-powered clinical decision support system that integrates trial matching, structured data extraction, and real-time oncology insights. The announcement highlights a broader industry shift: as AI becomes part of clinical
  • News
ConcertAI Expands CancerLinQ; Trust in Clinical AI Now Depends on Validation

EMA Launches Phased Reviews; Why GMP Submission Strategies Must Change

The European Medicines Agency (EMA) has started a phased review of daraxonrasib, an investigational therapy for metastatic pancreatic cancer. However, the biggest story is not the medicine itself. Instead, the review marks one of the first real-world applications of a
  • News
EMA Launches Phased Reviews; Why GMP Submission Strategies Must Change

AI Agents Enter Regulated Workflows; Penn Medicine Starts a New Healthcare Shift – Copy

Compass Pathways has reported new six-month Phase III data showing that its psilocybin-based therapy, COMP360, continued to provide durable clinical benefits for patients with treatment-resistant depression. While the efficacy results attracted attention, the announcement also moves the therapy closer to
  • News
COMP360 Nears FDA Approval; Validation Requirements May Soon Change